Cheratussin AC is commonly used to help with symptoms that create noticeable physiological strain, such as the persistent urge to cough during acute illness. The symptomatic management of these conditions is applicable within clinical settings that involve acute or disruptive symptom patterns, such as those seen in the common cold, flu, or respiratory infections, where non-productive coughing interferes with rest.

The medication may assist with managing the concurrent symptom of viscous chest congestion and is applied when patients experience accumulated, thick secretions. The therapy supports the easing of symptoms related to thick, tenacious mucus, which may contribute to improved comfort in the chest and assists with the natural process of clearance. The medication is commonly used to help with symptomatic relief for cough related to minor throat and bronchial irritation, and is applied in addressing mucus and phlegm.

This combination is generally used across therapeutic domains involving acute symptomatic episodes, providing supportive relief that helps patients cope more steadily with difficult episodes.

Quick Fact: Symptom Domain: Persistent Cough and Thick Mucus

This supportive relief contributes to easing the overall symptom load during periods of heightened respiratory discomfort.

Regulatory References

1. NIH DailyMed official drug label

The official regulatory profile for Cheratussin AC (Codeine Phosphate and Guaifenesin liquid) establishes strict population limitations primarily due to the opioid component.

Eligibility Scope

Scope	Regulatory Status
Populations for whom use is allowed:	Adults 18 years of age and older (The population to whom prescription codeine-containing antitussives are restricted)
Populations for whom use is contraindicated:	Children younger than 12 years of age; Breastfeeding women; Patients with known hypersensitivity to codeine or guaifenesin; Patients using MAOIs within the last 14 days.

Official Eligibility Statements

• Use is contraindicated in all patients younger than 12 years of age due to the risk of life-threatening respiratory depression.
• The product is also contraindicated for adolescent patients under 18 years following tonsillectomy and/or adenoidectomy.
• The use of this medicine is not recommended in pregnant individuals, and contraindicated for breastfeeding women.
• Use requires caution in patients with a history of substance use disorder, significant chronic obstructive pulmonary disease, severe hepatic impairment, or elevated intracranial pressure.

Connection to the Overall Eligibility Profile

The eligibility for Cheratussin AC is officially defined through mandatory exclusions, strictly limiting its indication to the adult population (18 years and older). Contraindications prohibit use based on age, physiological state (lactation), or concurrent medication use. Use is further conditioned on the absence of specific health conditions that increase the risk profile.

Cheratussin AC Interactions with other medicines and products

Official regulatory information outlines several categories of substances that interact with Cheratussin AC, primarily due to the Codeine component.

Interaction Type	Interacting Substance/Category	Official Restriction
Pharmacodynamic	CNS Depressants (e.g., alcohol, sedatives, other opioids, benzodiazepines)	Co-administration may result in profound sedation, respiratory depression, coma, and death; co-use is severely restricted and often avoided.
Pharmacodynamic	Monoamine Oxidase Inhibitors (MAOIs)	Contraindicated for co-use. The drug must not be administered within 14 days of stopping an MAOI.
Pharmacodynamic	Serotonergic Drugs (e.g., certain antidepressants)	Concurrent use may result in the development of Serotonin Syndrome.
Pharmacokinetic	CYP2D6 Inhibitors (e.g., Amiodarone)	May decrease the plasma concentration of the active metabolite (morphine), potentially reducing the drug's effect.
Pharmacokinetic	CYP3A4 Inhibitors/Inducers	May officially alter the plasma concentration of codeine, increasing or decreasing exposure to the parent drug.
Substance/Test	Alcohol	Avoid co-administration due to enhanced CNS depressant effects.
Substance/Test	Laboratory Tests	Guaifenesin may interfere with lab determinations of 5-HIAA and VMA.
Population-Specific	CYP2D6 Ultra-rapid Metabolizers	Contraindicated due to higher systemic active metabolite concentrations, posing a risk of life-threatening respiratory depression.

These official regulatory requirements define the critical safety boundaries for Cheratussin AC, focusing on high-risk combinations related to respiratory and central nervous system effects, as well as necessary restrictions regarding metabolic enzyme interactions.

Cheratussin AC is a combination product containing Codeine and Guaifenesin, each with distinct pharmacodynamic targets and cascades.

Codeine acts as a mu-opioid receptor agonist primarily within the central nervous system (CNS), specifically targeting neurons in the medulla that comprise the cough control center. Binding to the mu-opioid receptor, a G-protein coupled receptor, triggers the activation of the inhibitory G-protein Galphai, which consequently decreases intracellular cyclic adenosine monophosphate (cAMP) levels and inhibits voltage-gated calcium channels. This intracellular sequence leads to neuronal hyperpolarization and a reduction in neurotransmitter release, ultimately resulting in a systemic suppression of the cough reflex arc.

Guaifenesin's mechanism involves an action on respiratory tract fluid dynamics. It is proposed to stimulate gastric vagal receptors, initiating a gastro-pulmonary reflex that increases parasympathetic output to the respiratory glands. This systemic reflex action promotes an increased volume of bronchial secretions and a concomitant reduction in the viscosity of the mucin proteins and other components within the respiratory tract fluid. The resulting modulation of fluid viscoelasticity facilitates enhanced mucociliary clearance.

How to Use Cheratussin AC

The usage of Cheratussin AC is based on established parameters for the oral solution only. The medication is an oral liquid formulation, containing 10 mg of codeine phosphate and 100 mg of guaifenesin per 5 mL.

---

Official Dosing and Schedule

Population	Single Dose	Frequency and Limit
Adults (12 years)	10 mL	Every 4 hours; do not exceed 6 doses per 24 -hour period
Children (6 to under 12 years)	5 mL	Every 4 hours; do not exceed 6 doses per 24 -hour period

The syrup is typically taken with a full glass of water to support the action of the expectorant component. The solution may be taken with or without food; taking it alongside food or milk may help minimize potential gastrointestinal irritation.

---

Administration Conditions and Constraints

Accurate dosing requires the use of a specialized measuring device (such as a marked spoon or cup), and a common household spoon must not be used for measurement. Standard pediatric considerations indicate that children under 6 years require consultation with a doctor, and the product is restricted from use in children under 2 years.

The medication is designed for short-term use. If the underlying condition or cough persists for more than 7 days, or if it is accompanied by other severe symptoms, use should be discontinued and professional medical advice sought. These parameters represent the standard approach to using the medicine.

Research evidence / Overview of studies for Cheratussin AC

Evidence for use in Cough due to Common Cold or Allergies

Research has explored how the components of Cheratussin AC was studied for patterns in outcomes related to physical discomfort such as cough and chest congestion associated with the common cold or mild seasonal allergies. Research examined data describing episodic or acute changes in symptoms. These trials focused on short-term symptom changes and often used patient-reported outcomes describing perceived discomfort to document how participants felt during the study period.

Findings from these trials suggest that the medication may be was associated with patterns of change in the frequency and intensity of coughing spells linked to these conditions. The data show patterns related to temporary changes in symptoms while the underlying condition runs its course. However, the evidence quality varies across studies, and the certainty remains low for predicting how an individual person will respond.

---

Evidence for use in Respiratory Tract Irritation and Bronchitis

Studies have monitored the effects of the active ingredients in the setting of conditions associated with acute or disruptive episodes, such as minor irritation of the throat and bronchial tubes, or cough due to mild bronchitis. This research was studied for outcomes linked to inflammatory or irritative states where symptoms may vary in intensity. Studies report that changes were measured during the study period related to cough associated with excess mucus.

It is important to note that the results apply only to the populations studied, and the comparative evidence is lacking. The data for certain groups remain insufficient to draw broad conclusions about conditions involving periods of heightened symptoms such as those associated with chronic irritation.

---

Long-term studies and follow-up

Research has explored what happens after defined time intervals following the use of Cheratussin AC, especially since it is intended for short-term relief. There is limited information for long-term outcomes because the medicine is not typically used continuously over extended periods. Long-term effects are not fully established, and research is ongoing. The available data contributes to the broader evidence landscape by showing what has been observed in short-term symptom changes, but cannot speak to use beyond the recommended duration.

---

Evidence in special populations

The evidence landscape was evaluated in specific demographic groups, including older adults, as well as individuals living with comorbid conditions. Subgroup findings are uncertain in many areas because sample sizes were modest or the specific data for these groups remain insufficient. The evidence for use during pregnancy or breastfeeding is typically limited. Certainty remains low for making definitive statements about the outcomes related to systemic or functional imbalance in these populations.

---

What is still uncertain about Cheratussin AC

Despite the research, the findings were mixed in certain studies concerning the exact timing and consistency of symptom patterns across diverse individuals. The evidence highlights what is known — and what is still uncertain. Comparative evidence is lacking for this medication against other treatment approaches. Overall, the data are still emerging in several key areas, and the evidence provides context but not individual predictions.

Common questions about Cheratussin AC (FAQ)

Q: What is Cheratussin AC used for?

Cheratussin AC is a combination prescription medicine used to relieve cough and symptoms of the common cold or allergies. It contains two active ingredients:

• Codeine, a narcotic antitussive, works on the brain to decrease the urge to cough.
• Guaifenesin, an expectorant, helps to thin and loosen mucus in the lungs, making it easier to cough up.

Q: How should I take Cheratussin AC?

Cheratussin AC is typically taken by mouth, as a liquid solution. You should always follow your doctor's instructions exactly and use a special measuring device or spoon to ensure the correct dose. Do not use a household spoon.

• Take this medicine only as needed, and do not take more than prescribed or more often than every four to six hours.
• Do not stop taking the medicine suddenly without talking to your healthcare provider first.

Q: What are the common side effects of Cheratussin AC?

Common side effects of Cheratussin AC may include:

• Dizziness or drowsiness
• Lightheadedness
• Nausea and vomiting
• Constipation
• Headache
• Difficulty sleeping (insomnia)

If you experience severe constipation or symptoms of a serious allergic reaction (like difficulty breathing, swelling of your face/throat, or hives), seek medical attention immediately.

Q: Can I drink alcohol while taking Cheratussin AC?

No, you should strictly avoid drinking alcohol while taking Cheratussin AC. Alcohol can increase the risk of severe side effects, especially dangerous drowsiness, dizziness, and breathing problems, which can be life-threatening. The combination of alcohol and the codeine in this medication significantly depresses the central nervous system.

Q: What is the risk of addiction or dependence with Cheratussin AC?

Yes, there is a risk of physical and psychological dependence with Cheratussin AC because it contains codeine, an opioid. Taking this medication for a long time, or in doses higher than prescribed, increases this risk.

• Use this medication only for the shortest time needed and exactly as your doctor prescribes.
• If you have a history of substance use disorder, tell your doctor before starting this medicine.
• Do not share this medicine with anyone else.

Q: What should I do if I miss a dose?

If you miss a dose of Cheratussin AC, take the missed dose as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular dosing schedule. Do not take two doses at once to make up for a missed dose.

Storage and Disposal of Cheratussin AC

The official labeling requires Cheratussin AC (codeine phosphate and guaifenesin liquid) to be stored at Controlled Room Temperature, which is maintained between 20 to 25 C (68 to 77 F). The liquid must be protected from freezing, and storage excursions are limited to 15 to 30 C (59 to 86 F). The product must be kept in its original, tightly closed container.

Child Safety and Handling

Due to the presence of codeine, a controlled substance, the medication must be stored in a safe, secure place and kept out of the sight and reach of children to prevent accidental ingestion or misuse.

Disposal Instructions

For disposal of unused or expired medicine, a drug take-back program or authorized collection site is the preferred method. If a take-back option is unavailable, the liquid should be mixed with an unappealing substance, sealed in a container, and discarded in the household trash.